Classification
- Anatomical main groupLAntineoplastic and immunomodulating agents
- Therapeutic subgroupL04
- Pharmacological subgroupL04A
- Chemical subgroupL04AG
- Chemical substanceL04AG04Belimumab
Where it is registered
Each register and historical list with its number of registrations and a few of them.
Canada
Health Canada · 4 registrations
Netherlands
CBG-MEB · 4 registrations
At a glance
- ATC code
- L04AG04
- Registers
- 8
- Historical lists
- 2
- Registrations
- 24
- With their own page
- 17
- Companies
- 10
All medicines with Belimumab
Human medicines from every register that match Belimumab by substance or by name, a page at a time, so the count can differ from the registrations above. Strengths and packs are on each medicine’s page.
24 search results
| Medicine | Register | Strength | Form | Status | Holder |
|---|---|---|---|---|---|
| Benlysta | United States | 120MG, 200MG/ML, 400MG | injectable | Marketed | Human Genome Sciences INC. |
| Benlysta | United States | 200MG/ML | Injection | Marketed | GlaxoSmithKline LLC |
| Benlysta | European Union | Authorised | GlaxoSmithKline Trading Services Limited | ||
| Benlysta 200 MG Solucion Inyectable en Pluma Precargada | Spain | 200 mg | solución inyectable en pluma precargada | Marketed | Glaxosmithkline (Ireland) Limited |
| BENLYSTA 120 mg POLVO PARA CONCENTRADO PARA SOLUCION PARA PERFUSION | Spain | 120 mg | polvo para concentrado para solución para perfusión | Marketed | Glaxosmithkline (Ireland) Limited |
| BENLYSTA 400 mg POLVO PARA CONCENTRADO PARA SOLUCION PARA PERFUSION | Spain | 400 mg | polvo para concentrado para solución para perfusión | Marketed | Glaxosmithkline (Ireland) Limited |
| Benlysta | Canada | 120 MG / VIAL | Powder For Solution | Marketed | Glaxosmithkline INC |
| Benlysta | Canada | 400 MG / VIAL | Powder For Solution | Marketed | Glaxosmithkline INC |
| Benlysta | Canada | 200 MG / 1 ML | Solution | Marketed | Glaxosmithkline INC |
| Benlysta 120 mg, Poeder voor oplossing voor infusie | Netherlands | Poeder voor oplossing voor infusie | Authorised | GlaxoSmithKline (Ireland) Ltd. | |
| Benlysta 400 mg, Poeder voor oplossing voor infusie | Netherlands | Poeder voor oplossing voor infusie | Authorised | GlaxoSmithKline (Ireland) Ltd. | |
| Benlysta 200 mg oplossing voor injectie in voorgevulde pen | Netherlands | Oplossing voor injectie | Authorised | GlaxoSmithKline (Ireland) Ltd. | |
| Benlysta 200 mg oplossing voor injectie in voorgevulde spuit | Netherlands | Oplossing voor injectie | Authorised | GlaxoSmithKline (Ireland) Ltd. | |
| Benlysta | Brazil | Authorised | Glaxosmithkline Brasil Ltda | ||
| Benlysta | Croatia | Marketed | |||
| Benlysta Powder for Solution for Infusion 120mg | Singapore | 120mg/vial | injection, powder, lyophilized, for solution | Authorised | Glaxosmithkline Pte LTD |
| Benlysta Powder for Solution for Infusion 400mg | Singapore | 400mg/vial | injection, powder, lyophilized, for solution | Authorised | Glaxosmithkline Pte LTD |
| Benlysta | Saudi Arabia | Authorised | Glaxo Operations UK Ltd | ||
| Benlysta 120MG Powder for Solution for Infusion | Saudi Arabia | Authorised | Hospira | ||
| Benlysta 400MG Powder for Solution for Infusion | Saudi Arabia | Authorised | Hospira | ||
| Benlysta | Romania | 120 mg | pulb. pt. conc. pt. sol. perf. | Status unknown | Glaxosmithkline (Ireland) Limited |
| Benlysta | Canada | 200 MG / 1 ML | Solution | Cancelled | Glaxosmithkline INC |
| BENLYSTA 120mg | Romania | 120mg | pulb. pt. conc. pt. sol. perf. | Status unknown | Glaxo Group Limited |
| BENLYSTA 400mg | Romania | 400mg | pulb. pt. conc. pt. sol. perf. | Status unknown | Glaxo Group Limited |